CSL Behring

CSL Behring LLC
Industry Biopharmaceutical Health care
Headquarters King of Prussia, Pennsylvania
Key people
 Paul Perreault, CEO and Managing Director of CSL Limited
Number of employees
 20,000+[1]
Website http://www.cslbehring.com/

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[2]

CSL Behring operates the plasma collection network, CSL Plasma.[3]

Company Statistics

Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia
Headquarters: King of Prussia, PA
Employees: 19,000+[4]
Operations: In 30 countries
CEO and Managing Director: Paul Perreault[5]
R&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Kankakee, Illinois, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia.

History

CSL Behring is a member of the CSL Group of companies. Parent company CSL Limited (ASX: CSL) is a specialty biopharmaceutical company headquartered in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904.[6]

CSL Behring traces its heritage back to Emil von Behring, the inventor of serum therapy or serology.

YearEvent[7]
1901Emil von Behring received the Nobel Prize in Physiology or Medicine.[8]
1904Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines.
1913Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
1916CSL (then Commonwealth Serum Laboratories) was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand.
1917CSL produced 3 million doses of a mixed bacterial vaccine to combat the 1919 influenza pandemic.
1930CSL released its antivenom for tiger snake bites.
1940Armour Pharmaceuticals (a predecessor company) in Kankakee, Illinois, became a supplier of human albumin (the most abundant protein in human blood plasma) in World War II.
1944CSL began producing penicillin for the military and Australia to supply the drug to civilians at no charge.
1949ZLB (Zentrallaboratorium Blutspendedienst, a predecessor company) is established in Bern, Switzerland, as a department of the Swiss Red Cross and holds its first donor blood sessions in Switzerland.
1954Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL.
1966Rh(D) immunoglobulin, produced from plasma, is introduced by CSL for haemolytic disease in newborns.
1981Behringwerke introduces Haemate human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A.
1991CSL Limited is incorporated in Australia.
2000ZLB Bioplasma (a predecessor company) is established, acquiring the plasma fractionation assets from SRK, a nonprofit organization affiliated with the Swiss Red Cross.
2001Aventis Behring (a predecessor company) acquires 42 plasma centers.
2002RCMP lays criminal charges against Armour Pharmaceuticals.[9]
2004CSL Limited completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).
2007ZLB Behring becomes CSL Behring.
2009ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens the plasma testing laboratories in Knoxville, Tennessee.
2009National Organization for Rare Disorders (NORD) recognized CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.
2009CSL Behring awarded the Swiss government's Tell Award for innovations in manufacturing and protein therapies.
2012European Organisation for Rare Disorders recognized CSL Behring for its work developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.

Products

CSL Behring researches, develops, manufactures and markets a range of plasma-derived and recombinant products and related services, specializing in the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies; hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[1]

Immunology:

Coagulation/Bleeding Disorders:

Pulmonary:

  • Zemaira, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)

Critical Care:

  • AlbuRx, Alburex, Human Albumin Behring, Albuminar, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Beriplex P/N, Kcentra, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin P, freeze-dried human antithrombin III concentrate
  • Streptase, freeze-dried streptokinase

Wound Healing:

(Note: Product availability varies from country to country, depending on registration status.)

[10]

Offices

The company is headquartered in King of Prussia, Pennsylvania.[11] It has 14,000+ employees in 30 countries.[12] Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany, Kankakee, Illinois, and Broadmeadows, Australia.[13]

References

  1. ↑ http://cslbehring.com/about
  2. ↑ http://cslbehring.com/about
  3. ↑ http://cslplasma.com/about.htm
  4. ↑ http://cslbehring.com/about
  5. ↑ http://cslbehring.com/about/management-team.htm
  6. ↑ http://cslbehring.com/about/heritage-history.htm
  7. ↑ http://cslbehring.com/about/heritage-history.htm
  8. ↑ http://nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-bio.html
  9. ↑ "RCMP lay 32 charges in tainted-blood case".
  10. ↑ http://cslbehring.com/docs/555/221/Global%20Product%20Portfolio_03.11.10.pdf
  11. ↑ http://cslbehring.com/about/worldwide-locations.htm
  12. ↑ http://cslbehring.com/about
  13. ↑ http://cslbehring.com/about/worldwide-locations.htm#Manufacturing
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.